Back to search results

Home Exercise for Pulmonary Hypertension Interstitial Lung Disease

This study is looking at how a structured home exercise program can help people with pulmonary hypertension (high blood pressure in the lungs) and interstitial lung disease (a group of diseases that cause scarring of the lungs). You would participate in a 16-week home exercise program, either with aerobic exercise only or with both aerobic and strength training. The program messages would be sent daily by text or email. Researchers want to see if these programs can improve your functional ability, measured by changes in cardiac effort. To join, you must be an adult patient (over 18) with confirmed pulmonary hypertension interstitial lung disease, stable on your current treatment for at least 30 days, and have access to a smartphone or email. The study plans to enroll 30 participants.

Study design
This is an interventional study with 30 planned participants. It is not specified if it is randomized or blinded.
What's involved
You would follow a structured home exercise program for 16 weeks, receiving daily messages. You would have assessments at the beginning and end of this period.
Compensation
Not stated in the trial record.
Follow-up
Your progress will be assessed from the start of the study up to 16 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible ā€” confirm details with them before making decisions.

NCT07561034

The Benefits of Home Exercise in Pulmonary Hypertension Interstitial Lung Disease

Recruiting
NAAges 18+InterventionalTreatment
University of Rochester
~30 participants
Updated 2026-07-24 on ClinicalTrials.gov
What's tested:Home Exercise Program, Aerobic Plus Strength TrainingHome Exercise Program, Aerobic Only

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Mean Change in Cardiac Effort From Baseline to 16 Weeks
Measured over Baseline to 16 weeks

Conditions

Pulmonary Hypertension
Interstitial Lung Disease

Explore related trials

Pulmonary hypertension due to interstitial lung disease

Where it's being run

1 sites across 1 states
New York1

Who to contact

Daniel Lachant, DO
[email protected]
585 273 4608
Email the study team

Opens a ready-to-send draft in your own email app ā€” review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation ā€” and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min Ā· HIPAA-protected Ā· delete anytime
Eligibility criteria

Inclusion

Follows at University of Rochester Medical Center Pulmonary Hypertension Clinic.
Adult patients (\>18 years old) with right heart catheterization confirmed pulmonary hypertension interstitial lung disease on stable therapy dosing for at least 30 days.
Access to a smart phone or email to receive daily messages.
Clinically stable by the investigator.

Exclusion

Pregnancy.
Pulmonary Hypertension Groups 1,2,4,5.
Resting tachycardia \>120 beats/m during screening.
Inability to walk.
WHO Functional Class IV
Lack of access to email or text messaging.
Participating in a rehabilitation program.

What this trial measures

  • Mean Change in Cardiac Effort From Baseline to 16 WeeksBaseline to 16 weeks

    Cardiac Effort is measured as the ratio of the total number of heart beats recorded during the Six Minute Walk Test to the total distance walked in meters. Heart rate is continuously monitored during the test using a validated heart rate monitoring device. The value represents the number of heart beats required per unit distance walked (beats per meter). Individual participant values are calculated at baseline and at 16 weeks. The outcome is defined as the mean change in Cardiac Effort from baseline to 16 weeks across participants. Lower values indicate improved cardiac efficiency and better functional performance, while higher values indicate reduced efficiency and worse functional status.